The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters

被引:88
作者
Kouris, NT [1 ]
Zacharos, ID [1 ]
Kontogianni, DD [1 ]
Goranitou, GS [1 ]
Sifaki, MD [1 ]
Grassos, HE [1 ]
Kalkandi, EM [1 ]
Babalis, DK [1 ]
机构
[1] Western Attica Gen Hosp, Dept Cardiol, Athens, Greece
关键词
tumor marker; CA125; congestive heart failure;
D O I
10.1016/j.ejheart.2004.07.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess serum levels of carbohydrate antigen 125 (CA125) in patients with chronic congestive heart failure (CHF) and to assess any correlation with clinical symptoms and echocardiographic indices. Patients and methods: We enrolled 77 male patients (mean age: 73+/-10 years) admitted to the Cardiology Emergency Department (ED) with cardiac symptoms requiring hospitalization. Diagnosis of CHF was based upon medical history or initial echocardiographic evaluation on current admission. Serum CA125 was measured by an enzyme immunoradiometric assay, on admission and before discharge. Results: The median overall CA125 value was 22.4 (11.5-48.9) U/ml. Serum CA125 levels were related to the severity of CHF [New York Heart Association (NYHA) class I: 19.2 (7.2-31) U/ml, NYHA class II: 17.6 (10-23) U/ml, NYHA class III: 32 (25-77) U/ml and NYHA clas3 IV: 34.3 (18.6-77) U/ml (p<0.04)]. Patients in NYHA classes III and IV had significantly higher mean values of CA125, than patients in class H (p<0.005 and p<0.05, respectively). Moreover, patients with fluid congestion (pulmonary congestion, ankle edema) had higher levels of serum CA125 than patients without congestion (p=0.002 and p<0.03, respectively). Finally, levels of serum CA125 correlated weakly with right ventricular systolic pressure (RVSP) and renal function, while no significant correlation was found between CA125 and E wave deceleration time on Doppler echocardiography, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), liver function and the medical treatment prescribed. Conclusion: Serum CA125 is associated with the clinical severity of CHF and the symptoms and signs of fluid congestion and therefore may be a useful additional tool for the evaluation and clinical staging of these patients. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 29 条
[1]  
APEL RL, 1995, ARCH PATHOL LAB MED, V119, P373
[2]  
BARBIERI RL, 1986, FERTIL STERIL, V45, P630
[3]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[4]  
BERGMANN JF, 1987, CANCER-AM CANCER SOC, V59, P213, DOI 10.1002/1097-0142(19870115)59:2<213::AID-CNCR2820590206>3.0.CO
[5]  
2-I
[6]  
Camera A, 2000, CANCER, V88, P75, DOI 10.1002/(SICI)1097-0142(20000101)88:1<75::AID-CNCR11>3.0.CO
[7]  
2-#
[8]  
CANDOCIA SA, 1993, CANCER, V72, P2016, DOI 10.1002/1097-0142(19930915)72:6<2016::AID-CNCR2820720637>3.0.CO
[9]  
2-T
[10]   OVARIAN-CANCER ANTIGEN CA125 - A PROSPECTIVE CLINICAL-ASSESSMENT OF ITS ROLE AS A TUMOR-MARKER [J].
CANNEY, PA ;
MOORE, M ;
WILKINSON, PM ;
JAMES, RD .
BRITISH JOURNAL OF CANCER, 1984, 50 (06) :765-769